問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

柯伯彥Ko, Po-Yen
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

柯伯彥

List

19Cases

2011-04-01 - 2019-04-26

Phase III

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

  • Condition/Disease

    Atherosclerosis

  • Test Drug

    Canakinumab / ACZ885

Participate Sites
14Sites

Terminated14Sites

2012-09-01 - 2013-12-31

Phase II

A randomized, double-blind, crossover study to assess the effects of LCZ696 and valsartan in Asian patients with salt-sensitive hypertension.

  • Condition/Disease

    hypertension

  • Test Drug

    LCZ696

Participate Sites
4Sites

Terminated4Sites

2012-09-01 - 2013-12-31

Phase III

A randomized, 8-week, double-blind, parallel-group, active controlled, multicenter study to evaluate the efficacy and safety of the combination of LCZ696 200 mg + amlodipine 5 mg in comparison with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg monotherapy treatment.

  • Condition/Disease

    essential hypertension

  • Test Drug

    LCZ696

Participate Sites
5Sites

Terminated5Sites

2012-07-01 - 2013-06-30

Phase III

A 14 week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 in comparison to olmesartan in elderly patients with essential hypertension

  • Condition/Disease

    Essential Hypertention

  • Test Drug

    LCZ696

Participate Sites
10Sites

Terminated10Sites

2012-12-01 - 2016-08-31

Phase II

A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure in elderly patients with essential hypertension.

  • Condition/Disease

    ESSENTIAL HYPERTENSION

  • Test Drug

    LCZ696

Participate Sites
3Sites

Terminated3Sites

2014-04-15 - 2017-12-31

Phase III

A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

  • Condition/Disease

    Antidote for dabigatran

  • Test Drug

    Idarucizumab (BI 655075)

Participate Sites
5Sites

Terminated5Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

2013-12-01 - 2019-12-31

Phase III

Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Pf-04950615, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

  • Condition/Disease

    Major Cardiovascular Events

  • Test Drug

    PF-04950615

Participate Sites
10Sites

Terminated10Sites

2013-12-01 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB